ArticleBMC cardiovascular disorders2025
The impact of preoperative maintaining antithrombotic therapy in patients undergoing non-coronary endovascular interventions.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAntithrombotic medications, including antiplatelet and anticoagulant therapies, are widely used to prevent thromboembolic events in patients with cardiovascular diseases. It is common for patients on antithrombotic medications to undergo endovascular interventions though potential complications remain unclear. This study investigated the impact of continuing antithrombotic medications before endovascular interventions on perioperative clinical outcomes, particularly intraoperative blood transfusion.
methodsThis retrospective cohort study included patients who underwent endovascular interventions between January 2019 and December 2022. Patients were divided into four groups based on the preoperative antithrombotic medications: (1) those not receiving any antithrombotic therapy; (2) those receiving single antiplatelet therapy; (3) those receiving dual antiplatelet therapy; (4) those receiving anticoagulant therapy. Clinical outcomes, including blood transfusion, hematoma and pseudoaneurysm, were analyzed using multivariate logistics regression. Subsequently, patients were stratified based on whether they received blood transfusion. All-cause mortality, adverse cardiovascular events and infectious events were used to evaluate the impact of blood transfusion.
resultsA total of 5743 patients were included, with a mean age of 67.08 ± 14.27 years, and 69.81% of them were male. Common underlying conditions included hypertension (60.48%), vascular disease (28.75%), diabetes mellitus (22.60%), congestive heart failure (6.39%), and immune disease (4.21%). Compared to patients not receiving any antithrombotic medications, those undergoing dual antiplatelet therapy or anticoagulant therapy exhibited an increased risk of requiring blood transfusion (OR: 2.05, 95%CI: 1.30-3.23; OR: 1.92, 95%CI: 1.22-3.03). Subgroup analysis indicated that the risk of blood transfusion varied depending on the type of anesthesia, number of puncture sites and renal function, with a significant interaction (P < 0.05). Patients who required blood transfusion had a significantly higher rate of one-year all-cause mortality (HR: 2.18, 95% CI: 1.10-4.32) and three-month infectious events (HR: 4.92, 95% CI: 1.72-14.06).
conclusionsPreoperative maintaining dual antiplatelet or anticoagulant therapy increased the risk of blood transfusion in endovascular interventions. Blood transfusion was independently associated with increased risk of all-cause mortality and infectious events. These findings suggested the need for tailored perioperative management of antithrombotic therapy in patients undergoing endovascular interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.